Bacteriophages Targeting Vancomycin-Resistant Enterococci
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Vancomycin-resistant Enterococci (VRE) infections are challenging to treat due to intrinsic resistance to many antimicrobial agents, and existing antibiotics have limited effectiveness, leading to a need for alternative therapeutic agents.
Innovation Solution
Development of bacteriophages specifically targeting VRE, which can be formulated into compositions for prophylactic or therapeutic use, including oral, rectal, vaginal, and topical forms, to infect and lyse VRE, thereby reducing infection risk or treating existing infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum antibiotics are used to treat VRE infections, then bacterial infections are suppressed, but resistance development and side effects increase
Solution Approach 1:
Bacteriophages serve as intermediary agents that specifically target and infect VRE bacteria, delivering lytic enzymes that destroy bacterial cells without affecting human cells or promoting resistance. This mediator approach replaces direct antibiotic-bacteria interaction with a phage-mediated destruction mechanism.
Solution Approach 2:
The invention extracts and utilizes the natural lytic cycle mechanism of bacteriophages to specifically eliminate VRE bacteria. By taking out the phage infection and lysis process from natural ecosystems and applying it therapeutically, the system achieves targeted bacterial destruction without the harmful effects of antibiotics.
2Reliability
If existing antibiotics are used against VRE, then some infections are treated, but treatment effectiveness is limited due to intrinsic resistance
Solution Approach 1:
Instead of using antibiotics that attempt to inhibit bacterial growth through metabolic interference, the invention inverts the approach by using bacteriophages that actively infect and lyse bacterial cells from within. This reversal of the treatment mechanism overcomes intrinsic antibiotic resistance by employing a fundamentally different mode of action.
Solution Approach 2:
The invention changes the fundamental parameter of antimicrobial action from chemical inhibition (antibiotics) to biological infection and lysis (bacteriophages). This parameter change allows the system to bypass antibiotic resistance mechanisms while achieving effective bacterial elimination.
3Object-affected harmful factors
If bacteriophages are used to target VRE, then specific infection treatment is achieved, but formulation complexity increases
Solution Approach 1:
The bacteriophage composition is designed to perform multiple functions: infecting VRE bacteria, delivering lytic enzymes for bacterial destruction, and serving as a therapeutic agent. This multi-functionality consolidates several potential components into a single effective formulation, reducing overall complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bacteriophages effectively target and reduce VRE populations, offering a targeted approach that avoids the side effects associated with broad-spectrum antibiotics, thereby reducing invasive disease and transmission while maintaining a healthy gut microbiome.
Implementation Method 1
Bacteriophages are viruses that infect bacteria and lyse them as part of their replication/lytic cycle
Data Source
AI summary
Described herein are bacteriophages that infect and lyse Vancomycin-Resistant Enterococci (VRE). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with Enterococci, including VRE, or who are at risk of infection by Enterococci, including VRE, and for other uses described herein.